Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Integragen S.A. is a biotechnology company specializing in the field of genomics and molecular diagnostics. The primary focus of the company is to provide innovative solutions for the identification, analysis, and interpretation of genome variations, with an emphasis on applications that can aid in personalized medicine, notably within oncology and heritable diseases. Integragen works extensively in collaboration with researchers and healthcare providers to develop and deliver genome-based solutions that enhance the understanding of complex genetic disorders and aid in the development of targeted therapeutic strategies. The company's offerings include genomic services, data analysis, and custom bioinformatics solutions. Its significant role in the biotechnology sector comes from its contribution to advancing precision medicine through the harnessing of genomic data, impacting sectors ranging from cancer research to neurology. Integragen's capabilities in translating genomic data into actionable intelligence position it as a key player in the evolving landscape of healthcare innovation.
The business is unprofitable at the operating level (-0.94% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 4.8% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€13M
▼ -4.8% YoY
Net Income (TTM)
-€171K
▼ -4788.7% YoY
Op. Margin
-0.94%
▼ -0.4pp YoY
ROIC
-2.66%
▼ -1.6pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow
N/A
Net Debt
-€2M
Net Cash Position
Cash & Equiv.
€3M
3Y CAGR: +11.8%
Continue Research